Published in Oncogene on August 07, 2006
Reprogramming of human primary somatic cells by OCT4 and chemical compounds. Cell Stem Cell (2010) 3.82
Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis (2013) 3.07
Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev (2011) 2.97
Dynamic rerouting of the carbohydrate flux is key to counteracting oxidative stress. J Biol (2007) 2.70
Metabolic catastrophe as a means to cancer cell death. J Cell Sci (2007) 2.58
The molecular determinants of de novo nucleotide biosynthesis in cancer cells. Curr Opin Genet Dev (2009) 2.54
Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal (2009) 2.33
The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell (2012) 2.30
The metabolome of induced pluripotent stem cells reveals metabolic changes occurring in somatic cell reprogramming. Cell Res (2011) 2.30
Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol (2011) 2.24
Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis. Cancer Cell (2015) 2.21
Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J Cell Mol Med (2009) 2.13
AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol (2010) 2.11
The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr (2007) 2.07
Metabolite profiling of human colon carcinoma--deregulation of TCA cycle and amino acid turnover. Mol Cancer (2008) 2.02
Cancer as a metabolic disease. Nutr Metab (Lond) (2010) 1.98
Regulation of the fructose transporter GLUT5 in health and disease. Am J Physiol Endocrinol Metab (2008) 1.92
Synthesis enables identification of the cellular target of leucascandrolide A and neopeltolide. Nat Chem Biol (2008) 1.83
Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis? J Bioenerg Biomembr (2007) 1.83
Hypoxia inducible-factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells. Am J Pathol (2010) 1.79
MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nat Genet (2012) 1.70
A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY) (2010) 1.70
Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood (2008) 1.67
The ketogenic diet as a treatment paradigm for diverse neurological disorders. Front Pharmacol (2012) 1.61
Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer (2013) 1.57
GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol (2009) 1.54
A catabolic block does not sufficiently explain how 2-deoxy-D-glucose inhibits cell growth. Proc Natl Acad Sci U S A (2008) 1.54
The role of carbonic anhydrase 9 in regulating extracellular and intracellular ph in three-dimensional tumor cell growths. J Biol Chem (2009) 1.53
Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance. Drug Resist Updat (2008) 1.49
Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death. Cancer Res (2012) 1.49
Large-scale identification and analysis of suppressive drug interactions. Chem Biol (2014) 1.48
Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition. J Biol Chem (2009) 1.48
Targeting glycogen metabolism in bladder cancer. Nat Rev Urol (2015) 1.46
Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate (2010) 1.45
Mitochondrial dysfunction and reactive oxygen species imbalance promote breast cancer cell motility through a CXCL14-mediated mechanism. Cancer Res (2009) 1.42
Cancer metabolism: is glutamine sweeter than glucose? Cancer Cell (2010) 1.41
Mass spectrometry-based metabolomics of single yeast cells. Proc Natl Acad Sci U S A (2013) 1.41
Cancer cell metabolism: implications for therapeutic targets. Exp Mol Med (2013) 1.39
Hypoxia, glucose metabolism and the Warburg's effect. J Bioenerg Biomembr (2007) 1.37
Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res (2011) 1.35
Absence of the Birt-Hogg-Dubé gene product is associated with increased hypoxia-inducible factor transcriptional activity and a loss of metabolic flexibility. Oncogene (2010) 1.33
The glycolytic inhibitor 2-deoxyglucose activates multiple prosurvival pathways through IGF1R. J Biol Chem (2009) 1.30
Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro Oncol (2012) 1.29
Stable isotope-resolved metabolomics and applications for drug development. Pharmacol Ther (2011) 1.29
Cryptococcus neoformans requires a functional glycolytic pathway for disease but not persistence in the host. MBio (2011) 1.29
Dysregulated lipid metabolism in cancer. World J Biol Chem (2012) 1.27
3-Bromopyruvate: targets and outcomes. J Bioenerg Biomembr (2012) 1.27
Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol Med (2014) 1.27
Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: A pilot trial. Nutr Metab (Lond) (2011) 1.27
Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med (2011) 1.27
Hyaluronan, CD44, and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells. Cancer Res (2009) 1.26
Phosphorylation of eIF2α at serine 51 is an important determinant of cell survival and adaptation to glucose deficiency. Mol Biol Cell (2010) 1.25
Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma. Mol Cancer (2010) 1.24
Metabolic profiling reveals key metabolic features of renal cell carcinoma. J Cell Mol Med (2011) 1.23
Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides. BMC Cancer (2008) 1.23
Untuning the tumor metabolic machine: Targeting cancer metabolism: a bedside lesson. Nat Med (2012) 1.22
Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer (2011) 1.21
Evolutionary approaches to prolong progression-free survival in breast cancer. Cancer Res (2012) 1.19
Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy. PLoS One (2011) 1.18
Anticancer agents that counteract tumor glycolysis. ChemMedChem (2012) 1.17
Fucoidan extract induces apoptosis in MCF-7 cells via a mechanism involving the ROS-dependent JNK activation and mitochondria-mediated pathways. PLoS One (2011) 1.17
Aneuploidy: cancer's fatal flaw? Cancer Res (2009) 1.16
PDK1 inhibition is a novel therapeutic target in multiple myeloma. Br J Cancer (2012) 1.16
Direct inhibition of hypoxia-inducible transcription factor complex with designed dimeric epidithiodiketopiperazine. J Am Chem Soc (2009) 1.15
Rescue of myogenic defects in Rb-deficient cells by inhibition of autophagy or by hypoxia-induced glycolytic shift. J Cell Biol (2010) 1.15
Non-thermal plasma with 2-deoxy-D-glucose synergistically induces cell death by targeting glycolysis in blood cancer cells. Sci Rep (2015) 1.13
Potential role of sugar transporters in cancer and their relationship with anticancer therapy. Int J Endocrinol (2010) 1.13
A Sleeping Beauty mutagenesis screen reveals a tumor suppressor role for Ncoa2/Src-2 in liver cancer. Proc Natl Acad Sci U S A (2012) 1.12
Spatial colocalization and functional link of purinosomes with mitochondria. Science (2016) 1.12
Enhanced radiosensitivity and chemosensitivity of breast cancer cells by 2-deoxy-d-glucose in combination therapy. J Breast Cancer (2012) 1.11
Glycolytic phenotype in breast cancer: activation of Akt, up-regulation of GLUT1, TKTL1 and down-regulation of M2PK. J Cancer Res Clin Oncol (2009) 1.10
Simulating cancer growth with multiscale agent-based modeling. Semin Cancer Biol (2014) 1.09
The cancer cell's "power plants" as promising therapeutic targets: an overview. J Bioenerg Biomembr (2007) 1.09
Mitochondrial dysfunction and resuscitation in sepsis. Crit Care Clin (2010) 1.09
Metabolic signature identifies novel targets for drug resistance in multiple myeloma. Cancer Res (2015) 1.08
Mitocans as anti-cancer agents targeting mitochondria: lessons from studies with vitamin E analogues, inhibitors of complex II. J Bioenerg Biomembr (2007) 1.08
Antiangiogenic activity of 2-deoxy-D-glucose. PLoS One (2010) 1.08
mTORC1-Induced HK1-Dependent Glycolysis Regulates NLRP3 Inflammasome Activation. Cell Rep (2015) 1.06
Glycolysis is the primary bioenergetic pathway for cell motility and cytoskeletal remodeling in human prostate and breast cancer cells. Oncotarget (2015) 1.06
Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells. PLoS One (2011) 1.06
Graviola: a novel promising natural-derived drug that inhibits tumorigenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolism. Cancer Lett (2012) 1.06
Prosurvival Bcl-2 proteins stabilize pancreatic mitochondria and protect against necrosis in experimental pancreatitis. Exp Cell Res (2009) 1.06
Suppression of adenine nucleotide translocase-2 by vector-based siRNA in human breast cancer cells induces apoptosis and inhibits tumor growth in vitro and in vivo. Breast Cancer Res (2008) 1.06
Glucose starvation induces cell death in K-ras-transformed cells by interfering with the hexosamine biosynthesis pathway and activating the unfolded protein response. Cell Death Dis (2013) 1.05
Lactate dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma. Mol Cancer (2014) 1.05
Targeted killing of a mammalian cell based upon its specialized metabolic state. Proc Natl Acad Sci U S A (2011) 1.05
Mitochondria-targeted vitamin E analogs inhibit breast cancer cell energy metabolism and promote cell death. BMC Cancer (2013) 1.04
Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J Exp Clin Cancer Res (2015) 1.04
Rab25 increases cellular ATP and glycogen stores protecting cancer cells from bioenergetic stress. EMBO Mol Med (2012) 1.03
MRS and MRSI guidance in molecular medicine: targeting and monitoring of choline and glucose metabolism in cancer. NMR Biomed (2011) 1.03
Genome-wide RNAi screen identifies broadly-acting host factors that inhibit arbovirus infection. PLoS Pathog (2014) 1.03
Comparative proteomic approach identifies PKM2 and cofilin-1 as potential diagnostic, prognostic and therapeutic targets for pulmonary adenocarcinoma. PLoS One (2011) 1.03
ATP modulates PTEN subcellular localization in multiple cancer cell lines. Hum Mol Genet (2008) 1.03
Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning. Cancer Cell Int (2011) 1.02
Emerging metabolic targets in cancer therapy. Front Biosci (Landmark Ed) (2011) 1.02
Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine. Oncotarget (2014) 1.02
Advances of cancer therapy by nanotechnology. Cancer Res Treat (2009) 1.01
Polymeric nanoparticles for targeted treatment in oncology: current insights. Int J Nanomedicine (2015) 1.00
Targeting glycolysis in leukemia: a novel inhibitor 3-BrOP in combination with rapamycin. Leuk Res (2011) 1.00
New frontiers in nonhormonal male contraception. Contraception (2010) 1.00
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A (1998) 3.23
Gene expression profiling of cells, tissues, and developmental stages of the nematode C. elegans. Cold Spring Harb Symp Quant Biol (2003) 3.22
Protein secondary structures in water from second-derivative amide I infrared spectra. Biochemistry (1990) 2.69
Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol (1995) 2.57
Phylogenetic relationships among eight Eimeria species infecting domestic fowl inferred using complete small subunit ribosomal DNA sequences. J Parasitol (1997) 2.49
CpG ODN-induced matrix metalloproteinase-13 expression is mediated via activation of the ERK and NF-κB signalling pathways in odontoblast cells. Int Endod J (2013) 2.03
INTERSTITIAL BRONCHOPNEUMONIA : II. PRODUCTION OF INTERSTITIAL MONONUCLEAR PNEUMONIA BY THE BORDET-GENGOU BACILLUS. J Exp Med (1935) 2.02
A DYNAMIC METHOD FOR MEASUREMENT OF MUSCLE TONUS IN MAN. J Clin Invest (1930) 1.93
Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression. Oncogene (2010) 1.88
The Coventry Award. Polymerase chain reaction detection of bacterial infection in total knee arthroplasty. Clin Orthop Relat Res (1996) 1.83
The diverse roles of J-proteins, the obligate Hsp70 co-chaperone. Rev Physiol Biochem Pharmacol (2006) 1.83
Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol (1996) 1.81
The demise of a phylum of protists: phylogeny of Myxozoa and other parasitic cnidaria. J Parasitol (1995) 1.77
Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology (2006) 1.69
Telephone assistance for smoking cessation: one year cost effectiveness estimations. Tob Control (2004) 1.64
Relation of preoperative nerve-conduction values to outcome in workers with surgically treated carpal tunnel syndrome. J Hand Surg Am (1997) 1.54
G alpha(o) is necessary for muscarinic regulation of Ca2+ channels in mouse heart. Proc Natl Acad Sci U S A (1997) 1.48
The solitary intraspinal vertebral osteochondroma. An unusual cause of compressive myelopathy: features and literature review. Spine (Phila Pa 1976) (1999) 1.40
Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke (2000) 1.40
Heterogeneous nuclear ribonucleoprotein A1 regulates RNA synthesis of a cytoplasmic virus. EMBO J (2000) 1.38
Priming of insulin granules for exocytosis by granular Cl(-) uptake and acidification. J Cell Sci (2001) 1.37
Genotype and subtype analyses of Cryptosporidium isolates from dairy calves and humans in Ontario. Parasitol Res (2006) 1.37
Plasma levels of a viral protein as a diagnostic signal for the presence of tumor : the murine mammary tumor model. Proc Natl Acad Sci U S A (1976) 1.33
The effects of alcohols on lipid bilayers: a spin label study. Biochim Biophys Acta (1972) 1.33
Preclinical characteristics of gemcitabine. Anticancer Drugs (1995) 1.31
Role of murine tumor models in cancer treatment research. Cancer Res (1986) 1.30
In Vivo Neutralization of Pertussis Toxin with Pertussis Antitoxin. Am J Pathol (1943) 1.30
MAP 30: a new inhibitor of HIV-1 infection and replication. FEBS Lett (1990) 1.30
Endothelial nitric oxide synthase gene-deficient mice demonstrate marked retardation in postnatal bone formation, reduced bone volume, and defects in osteoblast maturation and activity. Am J Pathol (2001) 1.29
Polypyrimidine tract-binding protein binds to the leader RNA of mouse hepatitis virus and serves as a regulator of viral transcription. J Virol (1999) 1.28
Genome-wide analyses on loss of heterozygosity in hepatocellular carcinoma in Southern China. J Hepatol (2001) 1.24
Muscarinic cholinergic regulation of cardiac myocyte ICa-L is absent in mice with targeted disruption of endothelial nitric oxide synthase. Proc Natl Acad Sci U S A (1998) 1.23
A partial GDNF depletion leads to earlier age-related deterioration of motor function and tyrosine hydroxylase expression in the substantia nigra. Exp Neurol (2006) 1.23
2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest. Mol Pharmacol (2001) 1.22
Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway. Cell Death Differ (2013) 1.22
Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia (2008) 1.21
Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood (1997) 1.20
Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine. Leukemia (2004) 1.20
Evolutionary characterization of recent human H3N2 influenza A isolates from Japan and China: novel changes in the receptor binding domain. Arch Virol (1996) 1.19
Cryptosporidium is more closely related to the gregarines than to coccidia as shown by phylogenetic analysis of apicomplexan parasites inferred using small-subunit ribosomal RNA gene sequences. Parasitol Res (1999) 1.18
INTERSTITIAL BRONCHOPNEUMONIA : I. SIMILARITY OF A TOXIN PNEUMONIA TO THAT PRODUCED BY THE VIRUSES. J Exp Med (1935) 1.18
Sexual dimorphism in angiotensin II-induced hypertension and vascular alterations. Can J Physiol Pharmacol (2005) 1.18
Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia (2005) 1.18
Divergent functional properties of the ribosome-associated molecular chaperone Ssb compared with other Hsp70s. Mol Biol Cell (2001) 1.17
Identification of an N-terminal amino acid of the CLC-3 chloride channel critical in phosphorylation-dependent activation of a CaMKII-activated chloride current. J Physiol (2004) 1.17
Texas Tobacco Prevention Pilot Initiative: processes and effects. Health Educ Res (2004) 1.14
S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Res (2001) 1.13
Protection against TNF-induced lethal shock by soluble guanylate cyclase inhibition requires functional inducible nitric oxide synthase. Immunity (2000) 1.10
Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage. Cancer Res (2001) 1.09
TAP 29: an anti-human immunodeficiency virus protein from Trichosanthes kirilowii that is nontoxic to intact cells. Proc Natl Acad Sci U S A (1991) 1.09
Asymptomatic versus symptomatic herniated thoracic discs: their frequency and characteristics as detected by computed tomography after myelography. Neurosurgery (1991) 1.09
Plasma levels of a viral protein as a diagnostic signal for the presence of mammary tumor: the effect of tumor removal. J Exp Med (1977) 1.09
Atypical MR appearance of Lhermitte-Duclos disease with contrast enhancement. AJNR Am J Neuroradiol (1995) 1.07
Different vasculoprotective roles of NO synthase isoforms in vascular lesion formation in mice. Arterioscler Thromb Vasc Biol (2000) 1.06
Cloning and characterization of a cDNA encoding beta-amyrin synthase involved in glycyrrhizin and soyasaponin biosyntheses in licorice. Biol Pharm Bull (2001) 1.06
High-dose 5-fluorouracil with delayed uridine "rescue" in mice. Cancer Res (1982) 1.06
Distinct long-term neurocognitive outcomes after equipotent sevoflurane or isoflurane anaesthesia in immature rats. Br J Anaesth (2013) 1.04
Anti-HIV plant proteins catalyze topological changes of DNA into inactive forms. Biofactors (1992) 1.02
Age-related changes in synaptic function: analysis of the effect of dietary supplementation with omega-3 fatty acids. Neuroscience (1999) 1.01
A new class of anti-HIV agents: GAP31, DAPs 30 and 32. FEBS Lett (1991) 1.01
Redox-dependent changes in beta-extended chain and turn structures of cytochrome c in water solution determined by second derivative amide I infrared spectra. Biochemistry (1992) 1.01
Insulin-receptor and apolipoprotein genes contribute to development of NIDDM in Chinese Americans. Diabetes (1989) 1.00
Metabolism and action of fludarabine phosphate. Semin Oncol (1990) 0.99
Reduced expression of the μ opioid receptor in some, but not all, brain regions in mice with OPRM1 A112G. Neuroscience (2012) 0.98
Elimination of aggressive behavior in male mice lacking endothelial nitric oxide synthase. J Neurosci (1999) 0.98
Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol (1993) 0.96
Genetic and antigenic evidence supports the separation of Hepatozoon canis and Hepatozoon americanum at the species level. J Clin Microbiol (2000) 0.96
Inverse agonist up-regulates the constitutively active D3.49(164)Q mutant of the rat mu-opioid receptor by stabilizing the structure and blocking constitutive internalization and down-regulation. Mol Pharmacol (2001) 0.95
Mitomycin C reduces haze formation in rabbits after excimer laser photorefractive keratectomy. J Refract Surg (2001) 0.95
The conserved cysteine 7.38 residue is differentially accessible in the binding-site crevices of the mu, delta, and kappa opioid receptors. Biochemistry (2000) 0.95
Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance. Cancer Res (1983) 0.95
Surface analyses of micro-arc oxidized and hydrothermally treated titanium and effect on osteoblast behavior. J Biomed Mater Res A (2004) 0.94
Predictors of tobacco sales to minors. Prev Med (1997) 0.94
Insertion/deletion polymorphism in the angiotensin-converting enzyme gene and risk of restenosis after coronary angioplasty. Lancet (1995) 0.93
Endotoxin shock: a collective review. Rev Surg (1965) 0.93
Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. Leukemia (2006) 0.92
Molecular phylogeny of the other tissue coccidia: Lankesterella and Caryospora. J Parasitol (2001) 0.91
L-NA-sensitive rCBF augmentation during vibrissal stimulation in type III nitric oxide synthase mutant mice. J Cereb Blood Flow Metab (1996) 0.91
Increased susceptibility to development of triggered activity in myocytes from mice with targeted disruption of endothelial nitric oxide synthase. J Mol Cell Cardiol (2000) 0.91
The development of children with transient neonatal tyrosinemia. J Pediatr (1974) 0.90
Constitutive activation of the mu opioid receptor by mutation of D3.49(164), but not D3.32(147): D3.49(164) is critical for stabilization of the inactive form of the receptor and for its expression. Biochemistry (2001) 0.90
Effects of brain-derived neurotrophic factor on dopaminergic function and motor behavior during aging. Genes Brain Behav (2010) 0.90
An overview of thymidine. Cancer (1980) 0.90
DNA damage-induced phosphorylation of p53 at serine 20 correlates with p21 and Mdm-2 induction in vivo. Oncogene (2000) 0.90
Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation. Cancer (1980) 0.89
[Anti-inflammatory, analgesic and sedative effects of Leontice kiangnanensis P.L. Chiu]. Zhongguo Zhong Yao Za Zhi (1991) 0.89
Ultrasound triggered cell death in vitro with doxorubicin loaded poly lactic-acid contrast agents. Ultrasonics (2009) 0.89
Genome-wide allelotype analysis of sporadic primary nasopharyngeal carcinoma from southern China. Int J Oncol (2000) 0.89
Comparison of the amino acid residues in the sixth transmembrane domains accessible in the binding-site crevices of mu, delta, and kappa opioid receptors. Biochemistry (2001) 0.89
Carpal tunnel surgery outcomes in workers: effect of workers' compensation status. J Hand Surg Am (1995) 0.89
Biomarker discovery: identification of a growth factor gene signature. Clin Pharmacol Ther (2009) 0.89
Isolation and characterization of a gene encoding DNA topoisomerase I in Drosophila melanogaster. Nucleic Acids Res (1992) 0.89
Pre-treatment and post-treatment assessment of the C(6) test in patients with persistent symptoms and a history of Lyme borreliosis. Eur J Clin Microbiol Infect Dis (2004) 0.89
Regulation of switching and production of IgA in human B cells in donors with duplicated alpha1 genes. Eur J Immunol (2001) 0.89
Age-related changes in LTP and antioxidant defenses are reversed by an alpha-lipoic acid-enriched diet. Neurobiol Aging (2000) 0.89
[A preliminary report of the effect of levodopa and carbidopa for childhood amblyopia]. Yan Ke Xue Bao (1998) 0.88
Solitary intramedullary neurosarcoidosis: role of MRI in early detection. J Neuroimaging (2001) 0.88